Demographics and baseline characteristics of patients with newly diagnosed severe sarcoidosis-associated pulmonary hypertension
| Patients | 126 |
| Male/female | 65 (52)/61 (48) |
| Age years | 57.5±10.6 |
| BMI kg·m−2 | 25.5±6.6 |
| Tobacco exposure | 42 (33) |
| Time between sarcoidosis and pulmonary hypertension diagnosis months | 204 (59–313) |
| Radiological stage | |
| I | 6 (5) |
| II | 22 (17) |
| III | 7 (6) |
| IV | 91 (72) |
| WHO/NYHA functional class | |
| I–II | 21 (17) |
| III | 79 (63) |
| IV | 26 (20) |
| 6MWD m | 319±143 |
| Borg dyspnoea scale | 4.9±2.3 |
| Haemodynamics | |
| RAP mmHg | 7±5 |
| mPAP mmHg | 46±10 |
| PAWP mmHg | 9±4 |
| Cardiac index L·min−1·m−2 | 2.6±0.8 |
| PVR Wood units | 8.8±4.3 |
| SvO2 % | 63.4±8.9 |
| Lung function tests | |
| FVC % pred | 64±21 |
| FEV1 % pred | 55±22 |
| KCO % pred | 54±23 |
| Long-term oxygen therapy | 68 (54) |
Data are expressed as n, n (%), mean±sd or median (interquartile range). BMI: body mass index; WHO: World Health Organization; NYHA: New York Heart Association; 6MWD: 6-min walk distance; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; SvO2: mixed venous oxygen saturation; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; KCO: transfer coefficient of the lung for carbon monoxide.